Optimizing therapy regimen and companion diagnostics for multiple solid tumors
Indications: all targeted therapies for solid tumors
Relationship between cancer treatment and genetic testing
Cancer fundamentally is a genetic disease.
Therefore, tumor treatment can start from treating relevant genetic defects, affecting the characteristics of the tumor to achieve treatment. Studying cancer driver genes can indicate tumor progression, prognosis, recurrence and metastasis risk. Studying drug-related genes can guide targeted therapies and the sensitivity or resistance to certain drugs, etc. Understanding the genome of tumor is the start of of an effective treatment of cancer and can help achieve more precision treatment and maximize the clinical benefits.
Challenges of tumor precision diagnosis --- multitarget detection and combination treatment
Development of multi-dimensional auxiliary diagnostic system and real-world study
Non-invasive, continuous, real-time monitoring of molecular marker system and technology platforms
Liquid biopsy is one of the most effective ways to solve this problem
Liquid biopsy application
Growth and apoptosis of tumor cells are faster than normal cells; therefore there are greater amount of cell-free DNA(cfDNA) from tumor cells (ctDNA) existing in the peripheral blood of tumor patients. Genetic testing of these ctDNA will help guide cancer treatment
In the past 20 years, cancer has been redefined as a disease of genome.
Advantages and Characteristics
—— Solid tumor medication
Baishibo uses peripheral blood or tumor tissue samples for tumor related gene testing based on next generation sequencing. It helps to determine the sensitivity of targeted and chemotherapeutic drugs based on clinical evidence. The test covers all genes related to targeted therapies and chemotherapies approved by CFDA or FDA, drug-related genes evidenced by clinical trials and other cancer driver mutations. Baishibo provides patients with accurate, real-time and comprehensive information to guide treatments.
Genes associated with all targeted therapies and for pharmacogenetics of chemotherapy drugs approved and listed by CFDA and FDA (162 targets and 95 chemotherapeutics)
Driver gene mutations of various cancer types (Gene is various by cancer type)
Baishibo panel advantages:
Genecast focuses on individualized cancer treatment, based on publications, public database and proprietary internal database combined with meta analysis and attention to racial and ethnic differences
Genecast's gene panels specifically traget Chinese population (lung cancer, colorectal cancer, gastric cancer, liver cancer, esophageal cancer, endometrial cancer, ovarian cancer, cervical cancer, breast cancer, carcinoma tubae, malignocytoma of the head and neck and bladder cancer). And the panels are validated through a large number of samples with different cancer types.
Through detection and quantifications of different mutations, Genecast's results directly guide use of immune oncology drugs, targeted therapy drugs and chemotherapy drugs, and help to monitor cancer progressionthrough multifaceted data analysis and facilitate decisions on radiotherapy, surgery, etc..
Non-invasive liquid biopsy screen drug-related gene
Provide test for patients whose tissue samples hard to obtain
Precisely interpret genetic variations for drug efficacy
Provide deep sequencing of hotspots, rare unknown mutations
Provide real-time genetic profiling
Adjust treatment accordingly
Liquid biopsy overcomes the issue withtumor tissue heterogeneity
Reflect comprehensive tumor genetic mutation profile
Product Inspection Process: